Skip to main content Skip to footer

EviCore Announces Positive Coverage Guidelines For Heartflow Plaque Analysis To Extensive Network Of Commercial Payers. Click to read press release.

Heartflow One
Why CCTA
- CCTA Advantage
- Clinical Evidence
About
- About Us
- Careers
News
Contact
Login
Language selector
- United States
- Japan

Heartflow One
Why CCTA
- CCTA Advantage
- Clinical Evidence
About
- About Us
- Careers
News
Contact
Login
Language selector
- United States
- Japan

Contact Us Today

Product Support/General Inquiries

US
+1.877.HRT.FLOW  (+1.877.478.3569)

UK
+44 (2) 38903267

Press Inquiries
media@heartflow.com

Investor Inquiries
investor-relations@heartflow.com

Heartflow One

Platform Overview
Roadmap Analysis
FFR_CT Analysis
Plaque Analysis
Support

Why CCTA

CCTA Advantage
Clinical Evidence
Clinical Research
Reimbursement

About

About Us
Careers

News

Contact

Twitter
LinkedIn
YouTube
Heartflow App

Indications
Privacy Policy
Terms of Use
Modern Slavery Statement
Carbon Reduction Plan
Accessibility
Sitemap

Heartflow Analysis consists of four main functions; FFR_CT, Planner, Roadmap, and Plaque. All four functions are cleared for clinical use in 43 countries/regions, including the United States, United Kingdom and Europe. Only FFR_CT and Planner functions are cleared for clinical use in Canada, and Japan. Please see Heartflow Analysis Indications for Use and Instructions for Use for more information.

© 2025 Heartflow, Inc. | Heartflow and the Heartflow logo are registered trademarks of Heartflow, Inc. Additionally, Roadmap is claimed as a trademark of Heartflow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041